Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Dr. Dritschilo's presentation will be on Wednesday, March 6, 2024 at 11:25 am ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.Webcast presentation to take place at 11:25am ET
网络直播演示将于美国东部时间上午 11:25 举行
ROCKVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy ("RT"), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on March 6, 2024.
马里兰州罗克维尔，2024年3月5日（GLOBE NEWSWIRE）——专注于改善接受放射治疗（“RT”）治疗的癌症患者疗效的发现和开发阶段专业制药公司航天飞制药控股公司（纳斯达克股票代码：SHPH）今天宣布，其首席执行官阿纳托利·德里奇洛博士将参加2024年3月6日的新兴增长会议。
Dr. Dritschilo will present the Company's progress toward clinical and scientific milestones and subsequently open the floor to questions during the Conference. If you have any questions, please submit your questions in advance to Questions@EmergingGrowth.com.
Dritschilo博士将介绍公司在临床和科学里程碑方面的进展，随后在会议期间开放提问。如果你有任何疑问，请提前将问题提交到 Questions@EmergingGrowth.com。
Dr. Dritschilo's presentation will be on Wednesday, March 6, 2024 at 11:25 am ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.
德里奇洛博士的演讲将于美国东部时间2024年3月6日星期三上午11点25分举行。演示文稿的网络直播链接可以在公司网站的投资者关系页面上找到，也可以在此处访问。
If attendees are not able to join the event live on the day of the Conference, an archived webcast will also be made available on and on the Emerging Growth YouTube Channel,
如果与会者无法在会议当天直播参加活动，则还将在新兴增长YouTube频道上和新兴增长YouTube频道上提供存档的网络直播，
Dr. Dritschilo will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with Dr. Dritschilo and the Company's management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at SHPH@lythampartners.com.
会议结束后，德里奇洛博士还将主持一对一的投资者会议。要申请与Dritschilo博士和公司管理团队进行虚拟一对一会面，请联系您各自的新兴增长会议代表或发送电子邮件至公司的投资者关系团队 SHPH@lythampartners.com。
About Shuttle Pharmaceuticals
关于航天制药
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy ("RT"). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at .
Shuttle Pharmicals由乔治敦大学医学中心的教职员工于2012年创立，是一家处于发现和开发阶段的专业制药公司，专注于改善接受放射治疗（“RT”）治疗的癌症患者的预后。我们的使命是通过开发旨在最大限度地提高放射疗效同时限制放射在癌症治疗中的副作用的疗法，改善癌症患者的生活。尽管放疗是一种行之有效的癌症治疗方式，但通过开发辐射增敏剂，我们的目标是作为初级治疗或与手术、化疗和免疫疗法联合使用，提高癌症治愈率，延长患者存活率并改善生活质量。欲了解更多信息，请访问我们的网站。
Shuttle Pharmaceuticals
航天飞制药
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Anatoly Dritschilo，医学博士，首席执行官
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
投资者联系方式
莱瑟姆合伙人有限责任公司
罗伯特·布鲁姆
602-889-9700
shph@lythampartners.com